To mark #RareDiseaseDay on 29 February, our CEO Jean-Philippe Combal, spoke to pharmaphorum about the opportunities and challenges of developing therapies for rare diseases in 2024.
Jean-Philippe discussed the current challenges affecting the sector and provided insight into what the future holds for #rarediseases.
Read more about the landscape of rare disease therapies here: https://bit.ly/42XO86L
Vivet is commited to developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, learn more here: https://lnkd.in/dfPs38JV